Authors
Latest:
Managing Cancer-Related Fatigue in Women With Gynecologic CancersHanneke Poort, PhD, discusses the burden of cancer-related fatigue in women with gynecologic cancers; she also highlights a new intervention technique that is being used at Dana-Farber for these patients.
Latest:
Dr. Hans-Christian Kolberg on Safer Chemotherapy for Patients with HER2-positive Early Breast CancerHans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab for patients with HER2-positive early breast cancer.
Latest:
Positive Correlation With Patient-Reported Outcomes Seen in Phase III ENLIVEN TrialHans Gelderblom, MD, PhD, discusses the correlation between the overall response rate by Tumor Volume Score and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
Latest:
Future Management of Advanced RCCDr. Hammers discusses future management for advanced RCC, unmet needs, and emerging data being monitored.
Latest:
Methods Used for Ovary Suppression in Women with Breast CancerHarold J. Burstein, MD, PhD, a medical oncologist at the Dana-Farber Cancer Institute, explains how ovary suppression is done in patients with breast cancer. This is a particularly important treatment for younger women who still wish to have children one day.
Latest:
Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast CancerHarold J. Burstein, MD, PhD, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses a survey of how clinicians use genomic assays to assist in decision-making regarding the use of neoadjuvant and adjuvant chemotherapy for patients with ER-positive/HER2-negative early breast cancer.
Latest:
The Toxicity Profile of Concurrent Nivolumab and IpilimumabHarriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.
Latest:
Dr. Harry Bear on Translating Pathological Complete Response to OS BenefitsBear discusses studies adding treatments to chemotherapy in order to increase the pathological complete response (pCR) rate and the difficulties of translating those benefits into better overall survival (OS) rates for patients with breast cancer.
Latest:
Erba Explores myeloMATCH Substudies Targeting Genetic Diversity in AML, MDSHarry Erba, MD, PhD, discusses the specific substudies included in myeloMATCH.
Latest:
HER2 in Esophagogastric AdenocarcinomaDetermination of HER2 status has become an important part of the workup of patients with advanced esophagogastric cancer, given recent data from a phase III trial (ToGA) indicating that trastuzumab, an anti-HER2 monoclonal antibody, prolongs survival in these patients.
Latest:
The Challenges of Treating MesotheliomaHarvey I. Pass, MD, discusses some of the challenges of treating patients with mesothelioma
Latest:
The Future of Treating Head and Neck CancerHassan Arshad, MD, assistant professor of oncology, head and neck surgeon, Department of Head and Neck Surgery/Plastic and Reconstructive Surgery, Roswell Park Cancer Institute, discusses the future of treating head and neck cancer and the challenges behind treating the disease.
Latest:
Expert Cautions on Use of Antibiotics With Immunotherapy in MelanomaHassane M. Zarour, MD, discusses the addition of antibiotics to immunotherapy treatment in patients with melanoma.
Latest:
Soliman’s Key Takeaways for Managing HER2+ Breast CancerHatem Soliman, MD, highlights the crucial role of HER2 targeting and staying informed about evolving treatment options for better patient outcomes in the HER2-positive breast cancer space.
Latest:
Future Treatment Landscape for EGFR-mutated Non-Small Cell Lung CancerPanelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists for optimizing patient care in this rapidly changing field.
Latest:
Research Investigates Role of Antiangiogenic Agents and Checkpoint Inhibitors in EGFR NSCLCHeather A. Wakelee, MD, discusses recent research investigating antiangiogenic agents and checkpoint inhibitors in the frontline for patients with <em>EGFR</em>-positive non—small cell lung cancer. The most promising data were demonstrated in the phase III IMpower150 trial.
Latest:
Immunotherapy Advances Are Explored in Merkel Cell CarcinomaEarly-stage skin cancers that remain localized are often successfully treated through a variety of surgical techniques as well as radiation therapy, photodynamic therapy, and topical chemotherapy, but advanced cases that are beyond surgery may respond to immunotherapies. This setting will be discussed during the Society for Immunotherapy of Cancer’s 34th Annual Meeting.
Latest:
Genetic Testing Plays Larger Role in Treatment of Prostate CancerHeather H. Cheng, MD, PhD, discusses the role of genetic testing in prostate cancer as it continues to evolve in this space. This year, the 2019 NCCN guidelines focused more on genetic testing in select patients with prostate cancer.
Latest:
Efficacy of Perioperative Pembrolizumab/Chemotherapy in Early NSCLCHeather Wakelee, MD, discusses the efficacy findings from the phase 3 KEYNOTE-671 clinical trial evaluating the addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone for patients with early-stage non–small cell lung cancer.
Latest:
Differences Between Polycythemia Vera and Essential ThrombocythemiaHeinz Gisslinger, MD, Medical University of Vienna, discusses differences between polycythemia vera (PV) and essential thrombocythemia (ET).
Latest:
Analyzing the Importance of Biomarker Testing and MSI Status in mCRCHeinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate-142 trial.
Latest:
Integrating Advances in Immunotherapy into Treatment of mCRC in the CommunityHeinz-Josef Lenz, MD, FACP, discusses the advances in immunotherapy for treatment of metastatic colorectal cancer.
Latest:
Exploring Adaptive Drug Resistance in MelanomaHelmut Schaider, MD, associate professor, Dermatology Research Centre, The University of Queensland, Australia, discusses drug resistance in melanoma.<br />
Latest:
Rationale for Using TAS-102 in Patients With Gastric CancerHendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.
Latest:
The Paradigm Shift in the Management of Patients With Node-Positive Breast CancerHenry M. Kuerer, MD, PhD, FACS, from The University of Texas MD Anderson Cancer Center, discusses a paradigm shift in the management of patients with node-positive breast cancer.
Latest:
ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AMLClosing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.
Latest:
Exploring Immunotherapy Vaccines in GlioblastomaHideho Okada, MD, PhD, director, Brain Tumor Immunotherapy Center, professor of Neurological Surgery, University of California, San Francisco, discusses a study exploring vaccination in patients with glioblastoma.
